An early-phase study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine along with other Cancer Centers, suggests that an experimental therapy may have promising ...
May 26, 2023
0
4
A new study that used insights from the lab to drive a clinical trial for patients with a difficult-to-treat form of colorectal cancer improved patients' response to treatment and has yielded key insights with broad relevance ...
Jan 26, 2023
0
34
Researchers have identified a range of genetic alterations in glioma brain cancers that will help them to understand how different mutations in one particular gene interact with other gene alterations and which ones are more ...
Oct 26, 2022
0
27
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas MD Anderson Cancer Center showed in a study published today ...
Jun 15, 2022
0
51
Moles and melanomas are both skin tumors that come from the same cell called melanocytes. The difference is that moles are usually harmless, while melanomas are cancerous and often deadly without treatment. In a study published ...
Nov 23, 2021
0
33
Looking to understand why some brain tumors with a specific mutation can start to reject drugs commonly used to treat them, CU Cancer Center member Jean Mulcahy Levy, MD, led researchers from institutions around the country—including ...
Sep 15, 2021
0
34
Combining chemotherapy and BRAF oncogene inhibitors is an effective strategy for fighting metastatic melanoma, the leading cause of death from skin cancer in the world. This has been demonstrated in a study by researchers ...
Jul 13, 2021
0
2
Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study ...
Apr 28, 2021
0
10
Advanced melanoma is one of the deadliest types of cancer, with a 5-year survival rate of only 27% for patients with distant metastases. Recent advances in targeted therapies and immunotherapies have greatly improved patient ...
Mar 2, 2021
0
12
A new study led by researchers at the University of Kentucky Markey Cancer Center and UK Department of Pharmacology and Nutritional Sciences demonstrates the potential benefit of using an anti-leukemic drug nilotinib—most ...
Oct 30, 2020
2
66
